Search of anti-adriamycin antibodies in serum of cancer patients under chemotherapic treatment

A. Verdina, R. Tonachella, E. Colella, G. Falasca, Rosella Galati

Research output: Contribution to journalArticle


The exposure to DNA reactive carcinogens is known to elicit a specific humoral immunological response, with the production of antibodies towards the carcinogen adducts. In analogy to chemical carcinogens, any chemotherapic, like Adriamycin, undergoes the same adduct formation, and for this reason could elicit specific antibodies. In this case we can suppose that an eventual immunological response could influence the efficacy of chemotherapy. The aim of this study was to verify if adriamycin adducted to DNA or transport proteins can elicit an immunological response of specific anti-adriamycin (ADM) antibodies in sera of 43 cancer patients treated with the drug. No specific antibodies were detected in these individuals. The lack of anti-adriamycin antibodies suggests that the therapeutic exposure to the drug does not elicit a specific immunological response.

Original languageEnglish
Pages (from-to)337-340
Number of pages4
JournalJournal of Experimental and Clinical Cancer Research
Issue number3
Publication statusPublished - Sep 2002



  • Adriamycin
  • Immunological response
  • Specific antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this